ReviewJournal of clinical medicine2021
Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.Hepatology international · 2024Guideline
- From comics to care: exploring the education potential of graphic novel in organ transplantation journey.Medical humanities · 2026Article
- Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review.Journal of clinical medicine · 2026Review
- Advances and Emerging Techniques in Transarterial Chemoembolization for Hepatocellular Carcinoma.Cancers · 2026Review
- Impact of underlying liver etiology on post-hepatectomy survival outcomes in hepatocellular carcinoma patients.Translational cancer research · 2025Article
- Article
- Trends of liver transplantation in Asia.Updates in surgery · 2025Review
- Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation.Clinical and molecular hepatology · 2025Review
- Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.Annals of surgical oncology · 2025Article
- Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?World journal of transplantation · 2024Review
- An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.MedComm · 2024Article
- MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options.Current issues in molecular biology · 2024Review
- Article
- Review
- Development of a deep learning model for predicting recurrence of hepatocellular carcinoma after liver transplantation.Frontiers in medicine · 2024Article
- Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma.Abdominal radiology (New York) · 2023Review
- Changes in the Liver Transplant Waiting List after Expanding to the 'Up-to-Seven' Criteria for Hepatocellular Carcinoma.Journal of personalized medicine · 2023Article
- The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment.Clinical and molecular hepatology · 2023Review
- Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.World journal of transplantation · 2022Review
- Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review.Clinical and molecular hepatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Milan criteria (MC) were developed more than 20 years ago and are still considered the benchmark for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). However, the strict application of MC might exclude some patients who may receive a clinical benefit of LT. Several expanded criteria have been proposed. Some of these consider pretransplant morphological and biological variables of the tumor, others consider post-LT variables such as the histology of the tumor, and others combine pre- and post-LT variables. More recently, the HCC response to locoregional treatments before transplantation emerged as a surrogate marker of the biological aggressiveness of the tumor to be used as a better selection criterion for LT in patients beyond the MC at presentation. This essential review aims to present the current data on the pretransplant selection criteria for LT in patients with HCC exceeding the MC at presentation based on morphological and histological characteristics of the tumor and to critically discuss those that have been validated in clinical practice. Moreover, the role of HCC biological markers and the tumor response to downstaging procedures as new tools for selecting patients with a tumor burden outside of the MC for LT is evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.